CAR T cell News and Research

RSS

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

25 Mar 2021

New therapeutic vaccine uses patient's own tumor cells to aid in cancer destruction

Immunotherapy, which recruits the body's own immune system to attack cancer, has given many cancer patients a new avenue to treat the disease.

24 Mar 2021

Study explores how CAR T immunotherapy could be used to treat solid tumors

A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumors in addition to leukemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future.

18 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

An innovative cell-based treatment for cancer has been found promising for the control of infections caused by fungi.

4 Mar 2021

PICI awards $3 million to support early career cancer researchers

From improving immunotherapy response in childhood cancer patients, to better understanding how cancer's spread to the liver affects the body's immune system, to helping T cells stay energized to fight cancer, The Parker Institute for Cancer Immunotherapy (PICI)'s 2021 class of early career researchers award recipients are pursuing ideas that have the potential to change the face of oncology.

3 Mar 2021

ACGT awards $500,000 to advance immunotherapy approach for treating solid tumors

A scientific team led by Brian Brown, PhD, Professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has been awarded $500,000 from Alliance for Cancer Gene Therapy to advance a promising immunotherapy approach to fight lung cancer and other solid tumor cancers.

1 Mar 2021

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

24 Feb 2021

Understanding the dynamics of brain blood flow could hold key for treating neurologic conditions

While the human brain has over 400 miles of total vasculature, little is known about the tiny capillaries that make up much of this intricate labyrinth of blood vessels critical for delivering oxygenated blood and nutrients to billions of brain cells.

19 Feb 2021

Study reveals extremely low detection of SARS-CoV-2 on surfaces in oncology facilities

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.

18 Feb 2021

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

Researchers evaluate frequency of SARS-CoV-2 in hematology/oncology settings

18 Feb 2021

MSK researchers report an underlying cause of COVID brain

One of the dozens of unusual symptoms that have emerged in COVID-19 patients is a condition that's informally called "COVID brain" or "brain fog."

9 Feb 2021

$FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma$

FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma

Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

5 Feb 2021

Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients

Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

2 Feb 2021

Researchers identify protein that may represent a safer treatment target for pancreatic cancer

Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.

22 Jan 2021

Modified version of CAR T-cell therapy shows promise in targeting neuroblastoma

Chimeric Antigen Receptor T-cell therapy--CAR T--has revolutionized leukemia treatment. Unfortunately, the therapy has not been effective for treating solid tumors including childhood cancers such as neuroblastoma.

22 Jan 2021

Study investigates effect of anti-CD45 RIT lymphodepletion on immune cell types

Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric antigen receptor T cell therapies, and adoptive cell therapy in general, represent one of the most promising anti-cancer strategies.

12 Jan 2021

MDC researchers develop a potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

11 Jan 2021

CAR T cell News and Research

First cell-based gene therapy approved by the FDA for treating multiple myeloma

Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy

New therapeutic vaccine uses patient's own tumor cells to aid in cancer destruction

Study explores how CAR T immunotherapy could be used to treat solid tumors

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

PICI awards $3 million to support early career cancer researchers

ACGT awards $500,000 to advance immunotherapy approach for treating solid tumors

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

Understanding the dynamics of brain blood flow could hold key for treating neurologic conditions

Study reveals extremely low detection of SARS-CoV-2 on surfaces in oncology facilities

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Researchers evaluate frequency of SARS-CoV-2 in hematology/oncology settings

MSK researchers report an underlying cause of COVID brain

FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma

Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients

Researchers identify protein that may represent a safer treatment target for pancreatic cancer

Modified version of CAR T-cell therapy shows promise in targeting neuroblastoma

Study investigates effect of anti-CD45 RIT lymphodepletion on immune cell types

MDC researchers develop a potent weapon against lymphomas

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News